Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) plans to submit IND for TSR-022 (anti-TIM-3 antibody candidate) in Q2 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Management Comment "Finally, we’re advancing our immuno-oncology programs which phase 1 clinical trial of TSR-042 starting this quarter. We will submit the IND for TSR-022 in Q2 and we expect to select the clinical candidate targeting LAG-3 during the first half of this year.  By year end we intend to identify dosing schedule for TSR-042 as well as select five specific clinical candidate targeting PD-1 TIM-3 and PD-1 LAG-3."
-CEO Lonnie Moulder
http://seekingalpha....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ind-enabling Stage, Tsr-022, Anti-tim-3 Antibody, Antibody